Report #2896198

Received May 11, 2026

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Unknown
Age: Age unknown
State: AK
Recovered: Unknown
Vaccinated: —
Onset: —
Days to onset: —
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
HEP	HEP B (HEPLISAV-B)	DYNAVAX TECHNOLOGIES CORPORATION	2	—	—

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

Heplisav-B administered 3 days earlier than 1 month apart; Initial report received on 27-Apr-2026. A pharmacist reported that a patient (age, gender, race, and ethnicity unknown) received the second dose of HEPLISAV-B (hepatitis B vaccine) for hepatitis B immunization 3 days earlier than 1 month apart. No medical history or concomitant medications were reported. On an unknown date, the patient received dose 1 of a hepatitis B vaccine [HEPLISAV-B (Lot number, expiration date, NDC #, site, and route not reported). On an unknown date, 3 days earlier than 1 month after having been vaccinated with the first dose of HEPLISAV-B, the patient received the second dose of HEPLISAV-B (Lot number, expiration date, NDC #, site, and route not reported). No other information was available. Company Comment: The company assessed the event as non-serious.; Sender's Comments: The company assessed the event as non-serious.